European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its ...

What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...

AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, ...

The ex-CytoDyn chief exec must also forfeit more than $4.4 million—approximately the amount he profited from the scheme—and ...

The industry has learned how the ball bounces—now it must decide where to play next.  | While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” ...

A federal grand jury in Rhode Island has charged two former top executives of Colorado-based medical device company Zynex Inc. | A federal grand jury in Rhode Island has charged two former top ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

Fast-forward to 2026, and we’ve already seen a handful of U.S. biotechs line up to squeeze through a gradually reopening IPO ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...